多西他赛联合吉非替尼治疗晚期肺癌患者的临床研究  

Clinical Study of Docetaxel Combined with Gefitinib for Patients with Advanced Lung Cancer

作　　者：汪婷[1] 李宏[1] 王慧芳 向贵 盛盼 WANG Ting;Li Hong;WANG Huifang;XIANG Gui;SHENG Pan(Minimally lnvasive lnterventional Branch of Hubei Cancer Hospital,Wuhan,Hubei,430064,China;Department Outside People＇ s Hospital of Dongxihu District,Wuhan City,Wuhan,Hubei,430041,China)

机构地区：[1]湖北省肿瘤医院微创介入科,湖北武汉430064 [2]武汉市东西湖区人民医院外一科,湖北武汉430041

出　　处：《肿瘤药学》2018年第4期593-595,603,共4页Anti-Tumor Pharmacy

基　　金：国家自然科学基金项目(30873023);湖北省科技厅项目(2015CFC795)

摘　　要：目的探讨晚期肺癌患者应用多西他赛联合吉非替尼治疗的临床疗效及对患者生活质量的影响。方法选取在我院接受治疗的100例晚期肺癌患者,随机分成对照组和研究组。对照组患者采用吉非替尼单药治疗,研究组患者在对照组的基础上联合多西他赛治疗。观察两组患者的临床疗效、干预前后KPS和QOL评分、不良反应发生情况及CK-MB和射血分数变化。结果研究组临床疗效明显优于对照组(P<0.05);干预前,研究组KPS和QOL评分与对照组无明显差异(P>0.05);干预后,研究组KPS和QOL评分均明显优于对照组(P<0.05);研究组不良反应发生率明显低于对照组(P<0.05);研究组CK-MB和射血分数变化明显高于对照组(P<0.05)。结论采用多西他赛联合吉非替尼治疗晚期肺癌,可显著改善患者的临床疗效、延长生存期,值得临床推广使用。Objective To explore the clinical efficacy of docetaxel combined with gefitinib in patients with advanced lung cancer and its effects on quality of life （QOL） score of patients. Methods 100 patients with advanced lung cancer who received treatment in our hospital were randomly divided into a control group and a study group. Patients in the control group were treated with a single gefitinib regimen, and those in study group were treated with docetaxel combined gefitinib therapy. The clinical efficacy, KPS scores, QOL scores before and after intervention, adverse reactions and changes in CK-MB and ejection fraction were observed. Results The clinical efficacy of the study group was significantly better than that of the control group （P〈0.05）. Before the intervention, there was no significant difference in KPS score and QOL score between the study group and the control group （P〉0.05）. After the intervention, the KPS score and QOL score of the study group were significantly bet- ter than those of the control group （P〈 0.05）. The incidence of adverse reactions in the study group were significantly lower than in the control group （P〈0.05）. The changes of CK-MB and ejection fraction in the study group were significantly greater than those in the control group （P〈 0.05）. Conclusion In the process of the treatment of advanced lung cancer patients, docetaxel combined gefitinib therapy could signifi- cantly improve the clinical effects and prolong the survival of patients. This therapy could be further popularized in clinical practice.

关 键 词：多西他赛 吉非替尼 晚期肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]